ヒストン脱アセチル化酵素阻害剤 (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "ヒストン脱アセチル化酵素阻害剤" in Japanese language version.

refsWebsite

Global rank Japanese rank

4^th place

24^th place

2^nd place

6^th place

222^nd place

498^th place

18^th place

107^th place

1,248^th place

1,765^th place

1sciencedirect.com

149^th place

558^th place

5^th place

19^th place

1eurekaselect.com

low place

low place

low place

low place

1annualreviews.org

3,867^th place

5,881^st place

1aspetjournals.org

6,663^rd place

low place

2,814^th place

4,178^th place

1tandfonline.com

507^th place

1,847^th place

2,909^th place

low place

acs.org

pubs.acs.org

“Histone deacetylase inhibitors”. Journal of Medicinal Chemistry 46 (24): 5097–116. (November 2003). doi:10.1021/jm0303094. PMID 14613312.

annualreviews.org

“Clinical development of histone deacetylase inhibitors as anticancer agents”. Annual Review of Pharmacology and Toxicology 45: 495–528. (2005). doi:10.1146/annurev.pharmtox.45.120403.095825. PMID 15822187.

aspetjournals.org

molpharm.aspetjournals.org

“Rational development of histone deacetylase inhibitors as anticancer agents: a review”. Molecular Pharmacology 68 (4): 917–32. (October 2005). doi:10.1124/mol.105.014167. PMID 15955865.

cell.com

“The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension”. Trends in Pharmacological Sciences 26 (2): 94–103. (February 2005). doi:10.1016/j.tips.2004.12.009. PMID 15681027.

doi.org

“Histone deacetylase inhibitors”. Journal of Medicinal Chemistry 46 (24): 5097–116. (November 2003). doi:10.1021/jm0303094. PMID 14613312.
“Macrocyclic histone deacetylase inhibitors”. Current Topics in Medicinal Chemistry 10 (14): 1423–40. (2010). doi:10.2174/156802610792232079. PMC 3144151. PMID 20536416.
“Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group”. Bioorganic & Medicinal Chemistry 18 (1): 415–25. (January 2010). doi:10.1016/j.bmc.2009.10.042. PMC 2818366. PMID 19914074.
“Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?”. Drug Discovery Today 10 (3): 197–204. (February 2005). doi:10.1016/S1359-6446(04)03309-4. PMID 15708534.
“Histone deacetylases: unique players in shaping the epigenetic histone code”. Annals of the New York Academy of Sciences 983 (1): 84–100. (March 2003). Bibcode: 2003NYASA.983...84T. doi:10.1111/j.1749-6632.2003.tb05964.x. PMID 12724214.
“Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells”. Journal of the National Cancer Institute 92 (15): 1210–6. (August 2000). doi:10.1093/jnci/92.15.1210. PMID 10922406.
“Histone deacetylase inhibitors: overview and perspectives”. Molecular Cancer Research 5 (10): 981–9. (October 2007). doi:10.1158/1541-7786.MCR-07-0324. PMID 17951399.
“Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells”. Antioxidants & Redox Signaling 23 (1): 66–84. (July 2015). doi:10.1089/ars.2014.5863. PMC 4492771. PMID 24512308.
Wang, C.; Fu, M.; Angeletti, R. H.; Siconolfi-Baez, L.; Reutens, A. T.; Albanese, C.; Lisanti, M. P.; Katzenellenbogen, B. S. et al. (2001-05-25). “Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity”. The Journal of Biological Chemistry 276 (21): 18375–18383. doi:10.1074/jbc.M100800200. ISSN 0021-9258. PMID 11279135.
“Targeted histone deacetylase inhibition for cancer therapy”. Current Cancer Drug Targets 4 (2): 205–18. (March 2004). doi:10.2174/1568009043481560. PMID 15032670.
“Clinical development of histone deacetylase inhibitors as anticancer agents”. Annual Review of Pharmacology and Toxicology 45: 495–528. (2005). doi:10.1146/annurev.pharmtox.45.120403.095825. PMID 15822187.
“Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group”. International Journal of Cancer 121 (5): 1138–48. (September 2007). doi:10.1002/ijc.22751. PMID 17455259.
“Rational development of histone deacetylase inhibitors as anticancer agents: a review”. Molecular Pharmacology 68 (4): 917–32. (October 2005). doi:10.1124/mol.105.014167. PMID 15955865.
“The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension”. Trends in Pharmacological Sciences 26 (2): 94–103. (February 2005). doi:10.1016/j.tips.2004.12.009. PMID 15681027.
“HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention”. Oncogene 26 (37): 5310–8. (August 2007). doi:10.1038/sj.onc.1210599. PMID 17694074.
“Histone deacetylase isoforms regulate innate immune responses by deacetylating mitogen-activated protein kinase phosphatase-1”. J Leukoc Biol 95 (4): 651–9. (April 2014). doi:10.1189/jlb.1013565. PMID 24374966.
“Histone deacetylase inhibitors: possible implications for neurodegenerative disorders”. Expert Opinion on Investigational Drugs 17 (2): 169–84. (February 2008). doi:10.1517/13543784.17.2.169. PMID 18230051.
“HDAC2 negatively regulates memory formation and synaptic plasticity”. Nature 459 (7243): 55–60. (May 2009). Bibcode: 2009Natur.459...55G. doi:10.1038/nature07925. PMC 3498958. PMID 19424149.
“Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau”. The Journal of Neuroscience 28 (45): 11500–10. (November 2008). doi:10.1523/JNEUROSCI.3203-08.2008. PMC 2617713. PMID 18987186.
“The epigenetic code in depression: implications for treatment”. Clinical Pharmacology and Therapeutics 91 (2): 310–4. (February 2012). doi:10.1038/clpt.2011.282. PMID 22205200.
“The potential use of histone deacetylase inhibitors in the treatment of depression”. Progress in Neuro-Psychopharmacology & Biological Psychiatry 64: 320–4. (January 2016). doi:10.1016/j.pnpbp.2015.03.010. PMID 25818247.
“Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactions”. CNS Neuroscience & Therapeutics 17 (6): 699–704. (December 2011). doi:10.1111/j.1755-5949.2010.00203.X. PMC 3026916. PMID 20961400.
“Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability”. Genes 11 (5): 556–604. (May 2020). doi:10.3390/genes11050556. PMC 7288346. PMID 32429325.
“The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects”. Clinical Cancer Research 22 (10): 2534–2544. (May 2016). doi:10.1158/1078-0432.CCR-15-1666. PMID 26733615.
“HDAC inhibitors as anti-inflammatory agents”. British Journal of Pharmacology 150 (7): 829–31. (April 2007). doi:10.1038/sj.bjp.0707166. PMC 2013887. PMID 17325655.
“Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy”. PLOS Pathogens 10 (11): e1004473. (2014). doi:10.1371/journal.ppat.1004473. PMC 4231123. PMID 25393648.
“Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing”. PLOS Pathogens 10 (4): e1004071. (April 2014). doi:10.1371/journal.ppat.1004071. PMC 3983056. PMID 24722454.
“Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice”. FASEB Journal 22 (10): 3549–60. (October 2008). doi:10.1096/fj.08-108548. PMC 2537432. PMID 18606865.

eurekaselect.com

“Targeted histone deacetylase inhibition for cancer therapy”. Current Cancer Drug Targets 4 (2): 205–18. (March 2004). doi:10.2174/1568009043481560. PMID 15032670.

harvard.edu

ui.adsabs.harvard.edu

hdacis.com

“Histone deacetylase (HDAC) Inhibitors Database”. hdacis.com. 2015年10月6日閲覧。

nih.gov

pubmed.ncbi.nlm.nih.gov

“Histone deacetylase inhibitors”. Journal of Medicinal Chemistry 46 (24): 5097–116. (November 2003). doi:10.1021/jm0303094. PMID 14613312.
“Macrocyclic histone deacetylase inhibitors”. Current Topics in Medicinal Chemistry 10 (14): 1423–40. (2010). doi:10.2174/156802610792232079. PMC 3144151. PMID 20536416.
“Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group”. Bioorganic & Medicinal Chemistry 18 (1): 415–25. (January 2010). doi:10.1016/j.bmc.2009.10.042. PMC 2818366. PMID 19914074.
“Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?”. Drug Discovery Today 10 (3): 197–204. (February 2005). doi:10.1016/S1359-6446(04)03309-4. PMID 15708534.
“Histone deacetylases: unique players in shaping the epigenetic histone code”. Annals of the New York Academy of Sciences 983 (1): 84–100. (March 2003). Bibcode: 2003NYASA.983...84T. doi:10.1111/j.1749-6632.2003.tb05964.x. PMID 12724214.
“Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells”. Journal of the National Cancer Institute 92 (15): 1210–6. (August 2000). doi:10.1093/jnci/92.15.1210. PMID 10922406.
“Histone deacetylase inhibitors: overview and perspectives”. Molecular Cancer Research 5 (10): 981–9. (October 2007). doi:10.1158/1541-7786.MCR-07-0324. PMID 17951399.
“Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells”. Antioxidants & Redox Signaling 23 (1): 66–84. (July 2015). doi:10.1089/ars.2014.5863. PMC 4492771. PMID 24512308.
Wang, C.; Fu, M.; Angeletti, R. H.; Siconolfi-Baez, L.; Reutens, A. T.; Albanese, C.; Lisanti, M. P.; Katzenellenbogen, B. S. et al. (2001-05-25). “Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity”. The Journal of Biological Chemistry 276 (21): 18375–18383. doi:10.1074/jbc.M100800200. ISSN 0021-9258. PMID 11279135.
“Targeted histone deacetylase inhibition for cancer therapy”. Current Cancer Drug Targets 4 (2): 205–18. (March 2004). doi:10.2174/1568009043481560. PMID 15032670.
“Clinical development of histone deacetylase inhibitors as anticancer agents”. Annual Review of Pharmacology and Toxicology 45: 495–528. (2005). doi:10.1146/annurev.pharmtox.45.120403.095825. PMID 15822187.
“Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group”. International Journal of Cancer 121 (5): 1138–48. (September 2007). doi:10.1002/ijc.22751. PMID 17455259.
“Rational development of histone deacetylase inhibitors as anticancer agents: a review”. Molecular Pharmacology 68 (4): 917–32. (October 2005). doi:10.1124/mol.105.014167. PMID 15955865.
“The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension”. Trends in Pharmacological Sciences 26 (2): 94–103. (February 2005). doi:10.1016/j.tips.2004.12.009. PMID 15681027.
“HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention”. Oncogene 26 (37): 5310–8. (August 2007). doi:10.1038/sj.onc.1210599. PMID 17694074.
“Histone deacetylase isoforms regulate innate immune responses by deacetylating mitogen-activated protein kinase phosphatase-1”. J Leukoc Biol 95 (4): 651–9. (April 2014). doi:10.1189/jlb.1013565. PMID 24374966.
“Histone deacetylase inhibitors: possible implications for neurodegenerative disorders”. Expert Opinion on Investigational Drugs 17 (2): 169–84. (February 2008). doi:10.1517/13543784.17.2.169. PMID 18230051.
“HDAC2 negatively regulates memory formation and synaptic plasticity”. Nature 459 (7243): 55–60. (May 2009). Bibcode: 2009Natur.459...55G. doi:10.1038/nature07925. PMC 3498958. PMID 19424149.
“Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau”. The Journal of Neuroscience 28 (45): 11500–10. (November 2008). doi:10.1523/JNEUROSCI.3203-08.2008. PMC 2617713. PMID 18987186.
“The epigenetic code in depression: implications for treatment”. Clinical Pharmacology and Therapeutics 91 (2): 310–4. (February 2012). doi:10.1038/clpt.2011.282. PMID 22205200.
“The potential use of histone deacetylase inhibitors in the treatment of depression”. Progress in Neuro-Psychopharmacology & Biological Psychiatry 64: 320–4. (January 2016). doi:10.1016/j.pnpbp.2015.03.010. PMID 25818247.
“Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactions”. CNS Neuroscience & Therapeutics 17 (6): 699–704. (December 2011). doi:10.1111/j.1755-5949.2010.00203.X. PMC 3026916. PMID 20961400.
“Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability”. Genes 11 (5): 556–604. (May 2020). doi:10.3390/genes11050556. PMC 7288346. PMID 32429325.
“The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects”. Clinical Cancer Research 22 (10): 2534–2544. (May 2016). doi:10.1158/1078-0432.CCR-15-1666. PMID 26733615.
“HDAC inhibitors as anti-inflammatory agents”. British Journal of Pharmacology 150 (7): 829–31. (April 2007). doi:10.1038/sj.bjp.0707166. PMC 2013887. PMID 17325655.
“Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy”. PLOS Pathogens 10 (11): e1004473. (2014). doi:10.1371/journal.ppat.1004473. PMC 4231123. PMID 25393648.
“Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing”. PLOS Pathogens 10 (4): e1004071. (April 2014). doi:10.1371/journal.ppat.1004071. PMC 3983056. PMID 24722454.
“Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice”. FASEB Journal 22 (10): 3549–60. (October 2008). doi:10.1096/fj.08-108548. PMC 2537432. PMID 18606865.

ncbi.nlm.nih.gov

sciencedirect.com

“Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?”. Drug Discovery Today 10 (3): 197–204. (February 2005). doi:10.1016/S1359-6446(04)03309-4. PMID 15708534.

tandfonline.com

“Histone deacetylase inhibitors: possible implications for neurodegenerative disorders”. Expert Opinion on Investigational Drugs 17 (2): 169–84. (February 2008). doi:10.1517/13543784.17.2.169. PMID 18230051.

theweek.com

Gayomali, Chris (2013年4月29日). “Breakthrough: Is an HIV cure just a few months away?”. The Week (The Week Publications) 2013年9月12日閲覧。

wiley.com

nyaspubs.onlinelibrary.wiley.com

“Histone deacetylases: unique players in shaping the epigenetic histone code”. Annals of the New York Academy of Sciences 983 (1): 84–100. (March 2003). Bibcode: 2003NYASA.983...84T. doi:10.1111/j.1749-6632.2003.tb05964.x. PMID 12724214.

jlb.onlinelibrary.wiley.com

“Histone deacetylase isoforms regulate innate immune responses by deacetylating mitogen-activated protein kinase phosphatase-1”. J Leukoc Biol 95 (4): 651–9. (April 2014). doi:10.1189/jlb.1013565. PMID 24374966.

ascpt.onlinelibrary.wiley.com

“The epigenetic code in depression: implications for treatment”. Clinical Pharmacology and Therapeutics 91 (2): 310–4. (February 2012). doi:10.1038/clpt.2011.282. PMID 22205200.

worldcat.org

search.worldcat.org

Wang, C.; Fu, M.; Angeletti, R. H.; Siconolfi-Baez, L.; Reutens, A. T.; Albanese, C.; Lisanti, M. P.; Katzenellenbogen, B. S. et al. (2001-05-25). “Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity”. The Journal of Biological Chemistry 276 (21): 18375–18383. doi:10.1074/jbc.M100800200. ISSN 0021-9258. PMID 11279135.